• About us
• Contact

Advertisement

Organisation › Details

Arvelle Therapeutics GmbH

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. *

 

	Start	2019-02-14 established (approx)
	Group	Angelini (Group)
	Industry	CNS drug (neurological drug)
	Industry 2	cenobamate
	Person	Altmeyer, Mark (Arvelle Therapeutics 201902– CEO before Axovant Sciences + BMS + Otsuka America Pharmaceutical)
	Region	Zug ZG
	Country	Switzerland
	Street	6 Zählerweg
	City	6300 Zug ZG
		Address record changed: 2022-10-29
Basic data	Employees	n. a.
		* Document for »About Section«: Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel.
		Record changed: 2025-03-16

Advertisement

More documents for Angelini (Group)

• [1] Vantis. (3/12/25). "Press Release: Munich-based HealthTech Startup Vantis Secures 10 Million Euros in Series A Financing Round Led by Angelini Ventures". Munich....
• [2] Neumirna Therapeutics ApS. (1/8/25). "Press Release: Neumirna Therapeutics secures €20M in Series A financing to develop RNA therapies for epilepsy and other neurological disorders". Copenhagen....
• [3] Calluna Pharma AS. (10/9/24). "Press Release: Calluna Pharma Appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board". Oslo & Boston, MA....
• [4] Angelini Ventures S.p.A.. (3/21/24). "Press Release: Angelini Ventures Invests into Extended €75.8 Million ($82 Mmillion) Series C Financing Round for Nouscom". Rome....
• [5] Angelini Pharma. (7/28/21). "Press Release: Angelini Pharma and Lumira Ventures Launch the Angelini Lumira Biosciences Fund". Rome....
• [6] Arvelle Therapeutics GmbH. (1/4/21). "Press Release: Angelini Pharma Acquires Arvelle Therapeutics to Create a Leading European Innovator in Central Nervous System (CNS) and Mental Health Disorder Treatments". Rome....
• [7] Arvelle Therapeutics GmbH. (5/26/20). "Press Release: Arvelle Announces Closing of Final Tranche of Series A Financing Round". Zug....
• [8] Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.